Ausbiz Capital is now SureStone Capital. Same team, same ABN and AFS authorisations.
All Neurizon Therapeutics Limited (ASX:NUZ) announcement summaries, newest first. Every summary is drawn only from the company's official ASX release.

Neurizon receives FDA Type C feedback that positive HEALEY ALS results may support traditional approval and could serve as the single NDA study for NUZ-001.
06 Oct, 2026
An NIH grant to the Healey & AMG Center is expected to fund access to Neurizon's NUZ-001 for up to 200 people living with ALS, for up to 96 weeks, in the US.
09 Sep, 2026